Semax is one of the most discussed cognitive and neurologic peptides, often associated with focus, resilience, and neuroprotection.
Human studies exist in limited settings, but FDA found the evidence and safety information inadequate for the proposed compounding uses.
What a visitor should know.
Technical details: aliases, tracked claims, and data record
3 names in this peptide family.
Semax heptapeptide, free base, and acetate references resolve to the Semax family with route and form context preserved.
4 evidence questions.
Human benefitLimited human evidenceDoes Semax have established human clinical benefit for cerebral ischemia, migraine, and trigeminal neuralgia?
FDA approvalNo FDA approval identifiedIs Semax FDA approved?
503A statusRegulatory recordIs Semax on FDA's final 503A Bulks List or generally permitted because of committee activity?
Identity transferIdentity-sensitiveAre every product, alias, form, and related compound labeled Semax automatically interchangeable?
See every Semax evidence question →Open the machine-readable record ↗PCAC gave a favorable advisory recommendation
The committee recommended Semax-related bulk drug substances for possible inclusion on the 503A Bulks List.
FDA received advice from its expert compounding committee.
The compound was not FDA-approved, and the vote alone did not add it to the final 503A Bulks List.
How the FDA record developed.
This timeline separates early nominations and scientific reviews from committee votes and final FDA decisions.
PCAC gave a favorable advisory recommendation
The committee recommended Semax-related bulk drug substances for possible inclusion on the 503A Bulks List.
Read the source ↗FDA published its scientific briefing
FDA released its evaluation of Semax-related bulk drug substances for the committee meeting.
Read the source ↗Semax entered FDA's 503A nomination record
Two organizations nominated Semax-related substances. The nominations were later withdrawn, and FDA continued the evaluation on its own initiative.
Read the source ↗What has actually been studied?
Human studies appear on the left. Animal, cell, and laboratory studies appear on the right because they cannot establish that a treatment works in people.
Human studies exist in limited settings, but FDA found the evidence and safety information inadequate for the proposed compounding uses.
Read the FDA review ↗A published study compared 30 Semax-treated patients with 80 conventionally treated controls and reported faster neurologic recovery. The study was small and does not resolve FDA's concerns about design, product identity, route, or safety.
Read the study on PubMed ↗Preclinical findings were reviewed separately and do not establish clinical benefit in people.
Read the FDA review ↗Important unknowns.
- Human safety information is limited for the proposed routes and uses.
- FDA identified uncertainty around active-ingredient characterization, peptide-related impurities, or aggregation.
- Limited evidence of harm should not be interpreted as evidence of safety.
These are evidence and regulatory uncertainties, not an individualized assessment of whether a treatment is appropriate.
Read the original sources.
Technical change history and comparison data
3 dated changes. 3 comparison groups.
These records show what each source added and whether it changed Peplyst's public conclusion.